2,490 results found

The Canadian Intellectual Property Organization today released for comment their draft regulations designed to implement amendments to the Trademarks Act passed in 2014...

On November 22, 2017 the Federal Court issued a judgment granting Apotex's motion under s. 6(5)(b) of the PMNOC Regulations: Bristol-Myers Squibb et al v Apotex Inc et al, 2017 FC 1061.

Melanie Aitken stepped down as Commissioner of Competition on September 21, 2012, a post she held since 2009.

On June 12, 2019, the Canadian Agency for Drugs and Technologies in Health (CADTH) reported changes (effective July 1, 2019) to transition Cancer Drug Implementation

Certificate Of Supplementary Protection Filing Fee Increase Effective April 1, 2022.

On April 1, 2023, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,952 to $10,152 in accordance with subsection 9(1)...

On April 1, 2024, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $10,152 to $10,356 in accordance with subsection 9(1) of the Certificate...

On April 1, 2020, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,376 to $9,564 in accordance with subsection 9(1) of the...

On April 1, 2021, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,564 to $9,756 in accordance with subsection 9(1) of the Certificate of Supplementary...

The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.

On March 14, 2018, the Discipline Committee of the Ontario College of Pharmacists found that two directors of Costco pharmacies committed acts of professional misconduct ...

On February 27, 2018, the federal budget was tabled in the House of Commons. It announced the creation of an Advisory Council on the Implementation of National Pharmacare ...

The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling ...

As previously reported, the Patented Medicine Prices Review Board (PMPRB) extended the consultation period for its draft Guidelines to February 14, 2020. Submissions from the consultation...

The Patented Medicine Prices Review Board (PMPRB) has released its 7th edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2019/20.

On April 28, 2017, the Supreme Court of Canada dismissed Apotex's application for leave to appeal a decision of the Federal Court of Appeal

On February 5, 2018, Alexion Pharmaceuticals filed an application for leave to appeal a decision of the Federal Court of Appeal (FCA) ...

As previously reported, the Federal Court of Appeal dismissed Apotex's appeal from a decision holding that the claims of a patent relating to lisdexamfetamine (Shire's VYVANSE)...